Bibliography
- LAFFERTY KJ, CUNNINGHAM AJ: A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. (1975) 53:27–42.
- LIU Y, JANEWAY CAJ: Cells that present both specific ligand and the costimulatory activity are the most efficient inducer of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sd. USA (1992) 89:3845–3849.
- BROMLEY SK, IABONI A, DAVIS SJ et al: The immunological synapse and CD28-CD80 interactions. Nat. Innnunol. (2001) 2:1159–1166.
- BOISE LH, MINN AJ, NOEL PJ et al.: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-. Immunity (1995) 3:87–98.
- TAN P, ANASETTI C, HANSEN JA et al.: of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. 177:165–173.
- MUELLER DL, JENKINS MK, RH: Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev Inonunol. (1989) 7:445–480.
- AZUMA M, CAYABYAB M, BUCK D, PHILLIPS JH, LANIER LL: Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J. Inonunol. (1992) 149:1115–1123.
- AZUMA M, CAYABYAB M, BUCK D, JH, LANIER LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. I Exp. Med. (1992) 175:353–360.
- RAMARATHINAM L, CASTLE M, WU Y, LIU Y: T cell costimulation by B7/ BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. I Exp. Med. (1994) 179:1205–1214.
- BAI XF, BENDER J, LIU J, ZHANG H, WANG Y, LI O et al: Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. Immunol. (2001) 167:3936–3943.
- CHANG TT, JABS C, SOBEL RA, KUCHROO VK, SHARPE AH: Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. (1999) 190:733–740.
- ••Provides an immunological basis for B7–1 and B7-2 to prevent pre-existing autoimmune responses.
- BAI XF, LIU JQ, LIU X: The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. .1 Clin. Invest. (2000) 105:1227–1232.
- ••Provides an immunological basis fortargeted B7–1 and B7-2 to prevent pre-existing autoimmune responses.
- LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174:561–569.
- METZLER WJ, BAJORATH J, FEND ERSON W et al.: Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat. Struct. Biol. (1997) 4:527–531.
- ••Provides a structural basis for the B7-CTLA4 interaction.
- OSTROV DA, SHI W, SCHWARTZ JC, ALMO SC, NATHENSON SG: Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science (2000) 290:816–819.
- SCHWARTZ JC, ZHANG X, FEDOROV AA, NATHENSON SG, ALMO SC: Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 410:604–608.
- ••Provides a structural basis for the B7-CTLA4 interaction.
- CRISCIONE LG, ST CLAIR EW: Tumor necrosis factor-a antagonists for the treatment of rheumatic diseases. Curt: Opin. Rlieumatol. (2002) 14:204–211.
- FREEMAN BD, BUCHMAN TG: Interleukin-1 receptor antagonist as therapy for inflammatory disorders. Expert Opin. Biol. Ther. (2001) 1:301–308.